Therapeutic tools for oral candidiasis: Current and new antifungal drugs

En esta publicación en la revista Medicina Oral, Patología Oral y Cirugía Bucal realizamos una revisión sobre las herramientas terapéuticos existentes para el tratamiento farmacológico de las candidiasis orales. Es un estudio que hemos desarrollado, en la Facultad de Medicina y Enfermería de la Universidad del País Vasco (UPV/EHU), Sandra Gil-Alonso, Cristina Marcos-Arias, Elena Sevillano, Estibaliz Mateo, Nerea Jauregizar, Elena Eraso y Guillermo Quindós.

Este es el resumen:

BACKGROUND:

Candidiasis is one of the most common opportunistic oral infections that presents different acute and chronic clinical presentations with diverse diagnostic and therapeutic approaches. The present study carries out a bibliographic review on the therapeutic tools available against oral candidiasis and their usefulness in each clinical situation.

MATERIAL AND METHODS:

Recent studies on treatment of oral candidiasis were retrieved from PubMed and Cochrane Library.

RESULTS:

Nystatin and miconazole are the most commonly used topical antifungal drugs. Both antifungal drugs are very effective but need a long time of use to eradicate the infection. The pharmacological presentations of miconazole are more comfortable for patients but this drug may interact with other drugs and this fact should be assessed before use. Other topical alternatives for oral candidiasis, such as amphotericin B or clotrimazole, are not available in many countries. Oral fluconazole is effective in treating oral candidiasis that does not respond to topical treatment. Other systemic treatment alternatives, oral or intravenous, less used are itraconazole, voriconazole or posaconazole. Available novelties include echinocandins (anidulafungin, caspofungin, micafungin) and isavuconazole. Echinocandins can only be used intravenously. Isavuconazole is available for oral and intravenous use. Other hopeful alternatives are new drugs, such as ibrexafungerp, or the use of antibodies, cytokines and antimicrobial peptides.

CONCLUSIONS:

Nystatin, miconazole, and fluconazole are very effective for treating oral candidiasis. There are systemic alternatives for treating recalcitrant infections, such as the new triazoles, echinocandins, or lipidic presentations of amphotericin B.

Se puede acceder a la publicación en este enlace.

Views: 0